secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
CIK:        0001299130
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001299130-23-000022
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PacBio Q4 revenue down 24% YoY to $27.4M; net loss $84.4M; record Revio orders
------------------------------------------------------------------------------

- Q4 2022 GAAP net loss $84.4M ($0.37 EPS) vs $69.3M loss ($0.31 EPS) a year ago.
- Revenue $27.4M, down 24% YoY; instrument revenue fell 62% to $6.1M.
- Record orders for 96 instruments, including 76 Revio systems from 43 customers.
- Gross margin fell to 19% from 47%, impacted by $7.1M loss on purchase commitments.
- Raised ~$201M in January 2023 public offering; Revio commercial shipments begin March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000022/0001299130-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1299130/000129913023000022/pacb-20230216x8k.htm
  HTML page:      https://secwatch.observer/filing/0001299130-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer